Ayala Pharmaceuticals Inc (ADXS)

[hovacre]

I have little doubt that the pandemic slowed things down quite a bit, especially in 2020. A LOT of clinics were trying their hardest to make sure that patients were coming into infusion centers as little as possible. So a speculative trial like this one was going to be hard to continue to accrue. I would be interested in asking Ram someday about what slowed it down, and whether it was related to challenges with handling the Lm stuff. I've heard similar stories about dealing with Amgen's T-VEC from other doctors.


Very hard to say! But I've been keeping an eye out for results on ADXS's various platforms, despite their penny stock status. They're still trying to accomplish something.